Biogen Inc (BIIB – Q2FY20) – Look forward to grow from aducanumab in Alzheimer’s disease.

in , on September 14, 2020

Biogen Inc. and Denali Therapeutics Inc. announced that they have signed a binding agreement to codevelop and co-commercialize Denali’s small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson’s disease. Biogen will also receive rights to opt into two programs and a right of first negotiation for two additional programs, in each case for neurodegenerative diseases leveraging Denali’s Transport Vehicle (TV) technology platform to cross the blood-brain barrier (BBB).

Executive Summary

Financial Statements

– Income Statement and Forecast
– Balance Sheet
– Cash Flow
– Q2FY20 Results – Overview.
– 1HFY20 Results – Overview.
– Q2FY20 – Product Revenues
– Q2FY20 – Key Developments
– FY20 – Guidance
– Conclusion
– GAAP to Non-GAPP Reconciliation

Historical Performance

– Key Ratios
– Profitability Ratios, Asset Turnover Ratio, Growth Ratio
– Per Share Items and Key Ratios
– Key Cash Flow Items
– P/E Band

Product Performance and Key Developments

– Ownership
– Competition
– Key Developments

Valuation and Consensus Performance

– Analyst Recommendations

Market Price Performance

CrispIdea Coverage

No of Pages : 59


Release Information

  • Released

    September 14, 2020

  • Last Updated

    September 14, 2020